MyoKardia, Inc. (MYOK) Stake Increased by Teachers Advisors LLC

Teachers Advisors LLC increased its position in shares of MyoKardia, Inc. (NASDAQ:MYOK) by 42.1% during the fourth quarter, Holdings Channel reports. The fund owned 28,145 shares of the biotechnology company’s stock after buying an additional 8,342 shares during the period. Teachers Advisors LLC’s holdings in MyoKardia were worth $364,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the stock. Bessemer Group Inc. bought a new stake in shares of MyoKardia during the fourth quarter worth $114,000. Aberdeen Asset Management PLC UK bought a new stake in shares of MyoKardia during the fourth quarter worth $144,000. A.R.T. Advisors LLC bought a new stake in shares of MyoKardia during the fourth quarter worth $148,000. Trexquant Investment LP bought a new stake in shares of MyoKardia during the fourth quarter worth $210,000. Finally, Harbourvest Partners LLC bought a new stake in shares of MyoKardia during the fourth quarter worth $572,000. 47.74% of the stock is currently owned by institutional investors.

Institutional Ownership by Quarter for MyoKardia (NASDAQ:MYOK)

Shares of MyoKardia, Inc. (NASDAQ MYOK) opened at 14.30 on Tuesday. MyoKardia, Inc. has a 1-year low of $10.55 and a 1-year high of $22.83. The stock’s market capitalization is $449.81 million. The firm has a 50-day moving average price of $13.48 and a 200-day moving average price of $13.09.

MyoKardia (NASDAQ:MYOK) last released its quarterly earnings data on Tuesday, May 9th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by $0.01. The business had revenue of $5.60 million for the quarter, compared to analyst estimates of $7 million. MyoKardia had a negative return on equity of 15.27% and a negative net margin of 39.44%. The firm’s quarterly revenue was up 55.6% on a year-over-year basis. On average, equities research analysts forecast that MyoKardia, Inc. will post ($1.54) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by Ticker Report and is owned by of Ticker Report. If you are accessing this report on another site, it was stolen and republished in violation of United States & international copyright & trademark law. The original version of this report can be viewed at https://www.tickerreport.com/banking-finance/2654608/myokardia-inc-myok-stake-increased-by-teachers-advisors-llc.html.

A number of brokerages recently weighed in on MYOK. TheStreet raised MyoKardia from a “d” rating to a “c-” rating in a research report on Monday, March 13th. BMO Capital Markets reiterated an “outperform” rating and issued a $32.00 price target on shares of MyoKardia in a research note on Wednesday, May 10th. Wedbush reiterated an “outperform” rating and issued a $24.00 price target on shares of MyoKardia in a research note on Monday, March 13th. Finally, Zacks Investment Research cut MyoKardia from a “hold” rating to a “sell” rating in a research note on Thursday, May 11th. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $23.80.

MyoKardia Company Profile

MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:MYOK”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding MYOK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MyoKardia, Inc. (NASDAQ:MYOK).

Receive News & Ratings for MyoKardia Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyoKardia Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
President Trump Hurting Tourism in the U.S.
President Trump Hurting Tourism in the U.S.
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.